Seasonal Allergic Rhinitis LEVOZIN is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older. Perennial Allergic Rhinitis LEVOZIN is indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 months of age and older. Chronic Idiopathic Urticaria LEVOZIN is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.
LEVOZIN, the active enantiomer of cetirizine, is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. In vitro binding studies revealed that LEVOZIN has an affinity for the human H1- receptor 2- fold higher than that of cetirizine.
LEVOZIN is rapidly and extensively absorbed following oral administration. Peak plasma concentrations: 0.9 hour after administration of the oral tablet. Mean plasma protein binding: 91 to 92%. Volume of distribution: approximately 0.4 L/kg. Plasma half-life 8 to 9 hours Body clearance: approximately 0.63 mL/kg/min.
Usual Adult dose for Allergic Rhinitis & Urticaria 5mg orally once daily in the evening Pediatric Dose for Allergic Rhinitis and Urticaria 12 years or older: 5mg orally once daily in the evening 6 to 11 years old: 2.5 mg orally once daily in the evening 2 to 5 years old: 1.25 mg orally once daily in the evening.
Available in 5mg tablet Each strip contains 10 tablets